Vanda Pharmaceuticals, Inc. (VNDA) Posts Q2 Loss of 28c/Share
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.25 --0%
Revenue Growth %: +24.1%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q2 EPS of ($0.28), $0.01 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $8.38 million versus the consensus estimate of $8.3 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler lists 5 chip stocks to buy
- Monolithic Power Systems (MPWR) Reiterated at Buy by Stifel: Has Reached $4bn Target
- Vince Holding (VNCE) Tops Q2 EPS by 86c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
